Key result
In patients with non-valvular atrial fibrillation, the presence of significant valvular heart disease was associated with an increased risk of all-cause mortality (aHR 1.55) compared to no or mild disease.
Why the study?
Valvular heart disease in non-valvular AF is a puzzling clinical entity, prompting this study to evaluate the prognostic effect of significant VHD in these patients.
Does significant valvular heart disease worsen clinical outcomes in patients with non-valvular atrial fibrillation?
Cohort (n=983)
No
Does significant valvular heart disease worsen clinical outcomes in patients with non-valvular atrial fibrillation?
Hazard Ratio: 1.55 (95% CI 1.17–2.06)
Absolute Event Rate: 21.6% vs 1.6%
p-value: p=0.02
Significant valvular heart disease is highly prevalent in patients with 'non-valvular' atrial fibrillation and is independently associated with increased mortality and heart failure hospitalization.
May support risk stratification in non-valvular AF; leaves open effects on anticoagulation decisions.
Background: Valvular heart disease (VHD) in non-valvular atrial fibrillation (AF) is a puzzling clinical entity. The aim of this study was to evaluate the prognostic effect of significant VHD (sVHD) among patients with non-valvular AF. Methods: This is a post-hoc analysis of the MISOAC-AF trial (NCT02941978). Consecutive inpatients with non-valvular AF who underwent echocardiography were included. sVHD was defined as the presence of at least moderate aortic stenosis (AS) or aortic/mitral/tricuspid regurgitation (AR/MR/TR). Cox regression analyses with covariate adjustments were used for outcome prediction. Results: In total, 983 patients with non-valvular AF (median age 76 years) were analyzed over a median follow-up period of 32 months. sVHD was diagnosed in 575 (58.5%) AF patients. sVHD was associated with all-cause mortality (21.6%/yr vs. 1.6%/yr; adjusted HR [aHR] 1.55, 95% confidence interval [CI] 1.17-2.06; p = 0.02), cardiovascular mortality (16%/yr vs. 4%/yr; aHR1.70, 95% CI 1.09-2.66; p = 0.02) and heart failure-hospitalization (5.8%/yr vs. 1.8%/yr; aHR 2.53, 95% CI 1.35-4.63; p = 0.02). The prognostic effect of sVHD was particularly evident in patients aged <80 years and in those without history of heart failure (p for interaction < 0.05, in both subgroups). After multivariable adjustment, moderate/severe AS and TR were associated with mortality, while AS and MR with heart failure-hospitalization. Conclusion: Among patients with non-valvular AF, sVHD was highly prevalent and beared high prognostic value across a wide spectrum of clinical outcomes, especially in patients aged <80 years or in the absence of heart failure. Predominantly AS, as well as MR and TR, were associated with worse prognosis.
No takes yet. Share an insight, caveat, or question.
Σαμαράς et al. (2021) conducted a cohort in Non-valvular atrial fibrillation (n=983). Significant valvular heart disease (sVHD) vs. No or mild valvular heart disease was evaluated on All-cause mortality (aHR 1.55, 95% CI 1.17-2.06, p=0.02). In patients with non-valvular atrial fibrillation, the presence of significant valvular heart disease was associated with an increased risk of all-cause mortality (aHR 1.55) compared to no or mild disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: